For its second fiscal quarter (ending June 30), Integra LifeSciences Holdings Co (NASDAQ: IART) has reported E.P.S. of $-0.16 compared to $0.05 a year ago. For the latest four quarters through June 30, E.P.S. were $0.30 compared to $1.59 a year ago.
Recent Price Action
Integra LifeSciences Holdings Co (NASDAQ: IART) stock closed at $25.42 on 7/29/24 after a major decline of -19.1%. Moreover, trading volume in this decline was exceptionally high at 360% of normal. The stock has declined -18.9% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, IART is expected to continue to be an important Value Builder.
Integra LifeSciences Holdings has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Integra LifeSciences Holdings has a slightly positive Appreciation Score of 61 but a very low Power Rating of 8, producing the Negative Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment